{"id":"tetracycline-metronidazole","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal upset (nausea, diarrhea)"},{"rate":"5-10","effect":"Photosensitivity (tetracycline)"},{"rate":"5-15","effect":"Metallic taste (metronidazole)"},{"rate":"5-10","effect":"Vaginal candidiasis"},{"rate":"5","effect":"Headache"},{"rate":"<1","effect":"Peripheral neuropathy (metronidazole, rare)"}]},"_chembl":{"chemblId":"CHEMBL454950","moleculeType":"Small molecule","molecularWeight":"480.90"},"_dailymed":{"setId":"c50626a2-5969-490b-a88a-a4ee45e79615","title":"PYLERA (BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE) CAPSULE [H2-PHARMA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation. Metronidazole is a prodrug that generates reactive oxygen species and damages DNA/RNA in anaerobic organisms. Together, they provide broad-spectrum coverage against aerobic and anaerobic bacteria, commonly used in polymicrobial infections.","oneSentence":"This combination of tetracycline (a protein synthesis inhibitor) and metronidazole (a nucleic acid damaging agent) works synergistically to kill bacteria and anaerobic microorganisms through dual antimicrobial pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:11:53.783Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Polymicrobial infections including anaerobic bacteria"},{"name":"Periodontal disease and oral infections"},{"name":"Intra-abdominal infections"},{"name":"Mixed aerobic-anaerobic infections"}]},"trialDetails":[{"nctId":"NCT06561711","phase":"PHASE4","title":"Optimization of Minocycline for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-21","conditions":"Helicobacter Pylori Infection","enrollment":480},{"nctId":"NCT07487142","phase":"PHASE3","title":"Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding\"","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-10","conditions":"H Pylori Infection","enrollment":121},{"nctId":"NCT07455448","phase":"","title":"Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-03","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":7228},{"nctId":"NCT06943794","phase":"NA","title":"Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Gastric (Stomach) Cancer","enrollment":4824},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT07010744","phase":"NA","title":"Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Akil Al Islam","startDate":"2025-07-01","conditions":"Dyspepsia","enrollment":66},{"nctId":"NCT07358130","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2025-10-21","conditions":"Helicobacter Pylori Infection","enrollment":552},{"nctId":"NCT07312721","phase":"PHASE4","title":"Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis","status":"COMPLETED","sponsor":"Azfar Farogh","startDate":"2024-01-05","conditions":"Helicobacter Pylori Infection, Chronic Gastritis, Peptic Ulcer Disease","enrollment":752},{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT05206500","phase":"PHASE4","title":"NextGen - Clinical Implication of Next Generation Sequencing","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2022-05-17","conditions":"Urinary Tract Infections","enrollment":100},{"nctId":"NCT06027151","phase":"NA","title":"Comparing the Efficacy of Metronidazole and Minocycline Gels for the Treatment of Diabetic Periodontitis Patients","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2022-10-06","conditions":"Periodontitis, Diabetes Mellitus","enrollment":380},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT05874544","phase":"PHASE4","title":"Rescue Therapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-16","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT07165444","phase":"NA","title":"Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-09-11","conditions":"Potassium-Competitive Acid Blocker, Proton Pump Inhibitor, Bismuth Based Quadruple Therapy","enrollment":320},{"nctId":"NCT07144657","phase":"PHASE2","title":"Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-01","conditions":"MALT Lymphoma of Stomach","enrollment":40},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT05821478","phase":"PHASE3","title":"Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2025-05-22","conditions":"Hidradenitis Suppurativa","enrollment":92},{"nctId":"NCT06760065","phase":"PHASE3","title":"Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-15","conditions":"Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education","enrollment":316},{"nctId":"NCT05874570","phase":"PHASE4","title":"Doxycycline for Helicobacter Pylori Rescue Treatment","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-06-20","conditions":"Helicobacter Pylori Infection","enrollment":368},{"nctId":"NCT06332599","phase":"","title":"Minocycline for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-03-01","conditions":"Helicobacter Pylori Infection","enrollment":823},{"nctId":"NCT06561698","phase":"PHASE4","title":"High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-21","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT04531059","phase":"PHASE4","title":"Rescue Therapy for Helicobacter Pylori Eradication Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-10-15","conditions":"Helicobacter Pylori Infection","enrollment":368},{"nctId":"NCT02112214","phase":"PHASE3","title":"Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2014-06","conditions":"Gastric Cancer, Helicobacter Pylori Infection","enrollment":5224},{"nctId":"NCT06687473","phase":"PHASE4","title":"Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-01-01","conditions":"Helicobacter Pylori, Drug Resistance, Multiple, Virulence Factor","enrollment":13},{"nctId":"NCT06687499","phase":"PHASE4","title":"14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-08-22","conditions":"Helicobacter Pylori, Drug Resistance, Multiple","enrollment":46},{"nctId":"NCT05475431","phase":"","title":"Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Comorbidities and Coexisting Conditions, Real-world Outcome","enrollment":1053},{"nctId":"NCT06509139","phase":"PHASE4","title":"Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-07-09","conditions":"Helicobacter Pylori Infection, Sex, Bismuth Quadruple Therapy","enrollment":661},{"nctId":"NCT04527055","phase":"PHASE4","title":"The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication","status":"ENROLLING_BY_INVITATION","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Dysbiosis, Probiotics","enrollment":312},{"nctId":"NCT04147065","phase":"PHASE4","title":"Helicobacter Pylori Eradication According to DPO-PCR Methods (K-CREATE) Study)","status":"RECRUITING","sponsor":"Incheon St.Mary's Hospital","startDate":"2021-07-14","conditions":"Helicobacter Pylori Infection","enrollment":1230},{"nctId":"NCT03779074","phase":"PHASE3","title":"Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2018-09-03","conditions":"Helicobacter Pylori Infection","enrollment":918},{"nctId":"NCT03779087","phase":"NA","title":"Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection","status":"COMPLETED","sponsor":"Ping-I (William) Hsu, M.D.","startDate":"2018-07-11","conditions":"Helicobacter Pylori Infection","enrollment":112},{"nctId":"NCT01976065","phase":"PHASE1","title":"Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots","status":"COMPLETED","sponsor":"Kenneth Hargreaves","startDate":"2014-09","conditions":"Pulp Necrosis, Regeneration","enrollment":125},{"nctId":"NCT05049902","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-09-21","conditions":"Helicobacter Pylori Infection","enrollment":1300},{"nctId":"NCT05850117","phase":"NA","title":"Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2020-02-10","conditions":"Helicobacter Pylori Eradication","enrollment":240},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":"Appendicitis","enrollment":1552},{"nctId":"NCT02373280","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":600},{"nctId":"NCT02359331","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection","status":"TERMINATED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":370},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959},{"nctId":"NCT04853875","phase":"PHASE4","title":"ILTHPI - Comparison of Medicament Containing Tetracycline, Metronidazole, Bismuth Versus Amoxicillin, Metronidazole, Clarithromycin","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2021-04-19","conditions":"Helicobacter Pylori Infection","enrollment":104},{"nctId":"NCT04879992","phase":"NA","title":"Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-05-07","conditions":"Helicobacter Pylori Infection","enrollment":413},{"nctId":"NCT04723472","phase":"NA","title":"Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment","status":"SUSPENDED","sponsor":"Shanghai East Hospital","startDate":"2023-08-01","conditions":"Helicobacter Pylori Infection","enrollment":82},{"nctId":"NCT01426269","phase":"PHASE4","title":"Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2011-09","conditions":"Rosacea","enrollment":235},{"nctId":"NCT05449028","phase":"NA","title":"Helicobacter Pylori Eradication Therapy in Portugal","status":"UNKNOWN","sponsor":"Unidade Local de Saúde de Coimbra, EPE","startDate":"2022-05-01","conditions":"Helicobacter Pylori, Gut Microbiota, Immunology","enrollment":230},{"nctId":"NCT03148366","phase":"PHASE3","title":"Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Helicobacter","enrollment":560},{"nctId":"NCT03986996","phase":"PHASE2","title":"Antimicrobial Therapy for Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Wolfson Medical Center","startDate":"2019-07-25","conditions":"Ulcerative Colitis","enrollment":20},{"nctId":"NCT02345733","phase":"PHASE4","title":"Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis","status":"COMPLETED","sponsor":"Prof. Arie Levine","startDate":"2015-09-01","conditions":"Ulcerative Colitis (UC)","enrollment":20},{"nctId":"NCT05250050","phase":"PHASE4","title":"Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-03-25","conditions":"Helicobacter Pylori Infection","enrollment":388},{"nctId":"NCT05002595","phase":"","title":"H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2018-01-01","conditions":"H. Pylori Infection","enrollment":270},{"nctId":"NCT02756403","phase":"NA","title":"A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2016-03","conditions":"First Trimester Abortion","enrollment":181},{"nctId":"NCT04674774","phase":"NA","title":"Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Incheon St.Mary's Hospital","startDate":"2021-03-04","conditions":"Helicobacter Pylori Infection","enrollment":217},{"nctId":"NCT05126121","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Xiuli Zuo","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05135182","phase":"PHASE4","title":"Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-28","conditions":"Helicobacter Pylori Infection","enrollment":170},{"nctId":"NCT05133193","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05129176","phase":"PHASE4","title":"Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-23","conditions":"Helicobacter Pylori Infection","enrollment":106},{"nctId":"NCT05061732","phase":"PHASE4","title":"Helicobacter Pylori Eradication and Follow-up","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-09-30","conditions":"Helicobacter Pylori Infection","enrollment":4447},{"nctId":"NCT05018923","phase":"PHASE4","title":"Tetracycline Versus Doxycycline for HP Rescue Therapy","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08-24","conditions":"Helicobacter Pylori Infection","enrollment":242},{"nctId":"NCT04901117","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-06","conditions":"Helicobacter Pylori Infection","enrollment":1300},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02606032","phase":"PHASE2","title":"Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2016-05","conditions":"Ulcerative Colitis","enrollment":75},{"nctId":"NCT04107194","phase":"PHASE3","title":"Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.","status":"UNKNOWN","sponsor":"University of Bari","startDate":"2020-01-14","conditions":"Helicobacter Pylori Infection, Antibiotic Resistant Infection, Antibiotic Resistant Strain","enrollment":362},{"nctId":"NCT04082559","phase":"NA","title":"Biomarker-based Multidisciplinary Team (Bio-MDT) Approach to Personalized Microbial-targeted Treatment of Pouchitis and Crohn's Disease","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2019-06-11","conditions":"Inflammatory Bowel Diseases","enrollment":170},{"nctId":"NCT03658746","phase":"PHASE4","title":"Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shandong University","startDate":"2019-01-01","conditions":"Helicobacter Pylori Infection","enrollment":420},{"nctId":"NCT03565484","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-01-01","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT02490839","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT02557932","phase":"PHASE3","title":"Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2015-09","conditions":"Helicobacter Pylori Infection, Family History of Stomach Cancer","enrollment":352},{"nctId":"NCT00855595","phase":"PHASE4","title":"Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2009-02","conditions":"Papulopustular Rosacea","enrollment":207},{"nctId":"NCT03656484","phase":"PHASE2","title":"New Periodontitis Treatment Based on Hyaluronic Acid and Melatonin","status":"COMPLETED","sponsor":"Concordia Dent Srl","startDate":"2019-01-15","conditions":"Chronic Periodontitis","enrollment":50},{"nctId":"NCT03708848","phase":"PHASE4","title":"Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-12-05","conditions":"Helicobacter Pylori Infection","enrollment":112},{"nctId":"NCT04125706","phase":"NA","title":"Locally Delivered Antibiotics for the Treatment of Periodontitis","status":"UNKNOWN","sponsor":"Riyadh Elm University","startDate":"2019-11-01","conditions":"Periodontitis","enrollment":44},{"nctId":"NCT01967329","phase":"PHASE4","title":"CANHelp Working Group Treatment Trials","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2008-11","conditions":"Helicobacter Pylori Infection","enrollment":338},{"nctId":"NCT04066257","phase":"PHASE1","title":"Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2019-01-17","conditions":"Healthy","enrollment":32},{"nctId":"NCT02947763","phase":"PHASE1","title":"Single Versus Multiple Visits Endodontic Treatment","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-11","conditions":"Periapical Periodontitis","enrollment":44},{"nctId":"NCT04006340","phase":"NA","title":"Empirical vs Tailored Therapy for H. Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-01-04","conditions":"Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation, Helicobacter Pylori Infection","enrollment":62},{"nctId":"NCT02547038","phase":"NA","title":"Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2015-02","conditions":"Helicobacter Pylori Infection","enrollment":352},{"nctId":"NCT02159976","phase":"NA","title":"Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Helicobacter Pylori Infection","enrollment":390},{"nctId":"NCT03925818","phase":"NA","title":"Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication","status":"TERMINATED","sponsor":"Università degli Studi di Sassari","startDate":"2017-08-29","conditions":"Helicobacter Pylori Infection","enrollment":99},{"nctId":"NCT02483715","phase":"PHASE4","title":"Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-07","conditions":"Helicobacter Pylori Infection","enrollment":589},{"nctId":"NCT03727620","phase":"PHASE1, PHASE2","title":"Doxycycline in the Treatment of Aggressive Periodontitis","status":"COMPLETED","sponsor":"Mohammed V Souissi University","startDate":"2014-01-06","conditions":"Aggressive Periodontitis","enrollment":24},{"nctId":"NCT00002682","phase":"PHASE2","title":"Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1995-08-10","conditions":"Lymphoma","enrollment":5},{"nctId":"NCT02894268","phase":"PHASE4","title":"Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2016-02","conditions":"Helicobacter Pylori Infection","enrollment":300},{"nctId":"NCT01160640","phase":"PHASE2","title":"The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)","status":"COMPLETED","sponsor":"Harold Wiesenfeld","startDate":"2010-11","conditions":"Pelvic Inflammatory Disease","enrollment":233},{"nctId":"NCT01401023","phase":"NA","title":"Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Gary E. Stein, Pharm.D.","startDate":"2011-07","conditions":"Diarrhea, Clostridium Difficile","enrollment":10},{"nctId":"NCT03571230","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-07-01","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":400},{"nctId":"NCT03555526","phase":"PHASE4","title":"Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-12-15","conditions":"H Pylori Infection","enrollment":320},{"nctId":"NCT03208426","phase":"PHASE4","title":"Sequential Versus Quadruple Therapy in the Second-line Treatment","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-10-01","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT03361267","phase":"NA","title":"Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection","status":"UNKNOWN","sponsor":"Inha University Hospital","startDate":"2017-12-30","conditions":"Helicobacter Pylori Infection, Compliance, Patient, Drug Resistance","enrollment":300},{"nctId":"NCT02541864","phase":"NA","title":"Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2013-07","conditions":"Helicobacter Pylori Infection","enrollment":330},{"nctId":"NCT03322488","phase":"NA","title":"Fistulodesis Pilot Study for Closure of Perianal Fistulae","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2017-06-20","conditions":"Perianal Fistula, Crohn Disease","enrollment":40},{"nctId":"NCT00016835","phase":"PHASE2","title":"Treating Periodontal Infection: Effects on Glycemic","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2001-10-17","conditions":"Periodontal Disease, Diabetes Mellitus, Type 2","enrollment":46},{"nctId":"NCT01906879","phase":"PHASE4","title":"Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2013-06","conditions":"Helicobacter Pylori Infection","enrollment":1620},{"nctId":"NCT03156855","phase":"PHASE4","title":"Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2015-09","conditions":"Helicobacter","enrollment":620},{"nctId":"NCT03146325","phase":"PHASE4","title":"Helicobacter Pylori and Body Iron in Adults","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2012-11","conditions":"Helicobacter Pylori Infection","enrollment":""},{"nctId":"NCT01725906","phase":"PHASE4","title":"Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-11","conditions":"Self Efficacy","enrollment":450},{"nctId":"NCT03139253","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Yanqing Li","startDate":"2017-05-30","conditions":"Antimicrobial Susceptibility Testing, Triple Therapy","enrollment":120},{"nctId":"NCT02988089","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2017-04-20","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":480},{"nctId":"NCT00669955","phase":"PHASE3","title":"Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-06","conditions":"Helicobacter Infections","enrollment":440},{"nctId":"NCT00712413","phase":"PHASE3","title":"Safety, Efficacy of Pylera BID Dosing in Eradication of H. Pylori","status":"WITHDRAWN","sponsor":"Forest Laboratories","startDate":"2008-08","conditions":"Helicobacter Pylori Infection","enrollment":""},{"nctId":"NCT00841854","phase":"PHASE4","title":"Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2008-06","conditions":"Helicobacter Infection","enrollment":199},{"nctId":"NCT02934048","phase":"PHASE4","title":"Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2016-10","conditions":"Therapeutic Duration, Helicobacter Pylori, Antimicrobial Susceptibility Test","enrollment":700},{"nctId":"NCT02349685","phase":"NA","title":"The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-01","conditions":"Helicobacter Infection","enrollment":219}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DERMATITIS EXFOLIATIVE GENERALISED"}],"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tetracycline,Metronidazole","genericName":"Tetracycline,Metronidazole","companyName":"Shanghai Jiao Tong University School of Medicine","companyId":"shanghai-jiao-tong-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of tetracycline (a protein synthesis inhibitor) and metronidazole (a nucleic acid damaging agent) works synergistically to kill bacteria and anaerobic microorganisms through dual antimicrobial pathways. Used for Polymicrobial infections including anaerobic bacteria, Periodontal disease and oral infections, Intra-abdominal infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}